Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4019022 | 1.00 | KIF11 (0.37) | KIF11HRH3ACHEP2RX7KDM4E | |
| SCHEMBL4025178 | 0.94 | KIF11 (0.45) | KIF11HRH3ACHEP2RX7ALDH1A1 | |
| SCHEMBL4024600 | 0.89 | L3MBTL1 (0.34) | KIF11ALDH1A1RORCSLC6A1 | |
| SCHEMBL4027448 | 0.89 | KDM2B (0.37) | KIF11ALDH1A1RORC | |
| SCHEMBL4026679 | 0.89 | L3MBTL1 (0.34) | KIF11ALDH1A1RORCSLC6A1 | |
| SCHEMBL4026766 | 0.88 | KIF11 (0.41) | KIF11ALDH1A1RORCSLC6A1 | |
| SCHEMBL4021821 | 0.88 | KIF11 (0.41) | KIF11ALDH1A1RORCSLC6A1 | |
| SCHEMBL4027189 | 0.87 | KCNH2 (0.35) | KIF11ALDH1A1RORCSLC6A1 | |
| SCHEMBL4020571 | 0.87 | KCNH2 (0.35) | KIF11ALDH1A1RORCSLC6A1 | |
| SCHEMBL4028852 | 0.86 | KCNH2 (0.37) | KIF11ALDH1A1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | KIF11 3745/4885HRH3 1935/4885ACHE 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.